Research Priorities
Gates MRI focuses on programs aimed at reducing the burden of tuberculosis (TB) and malaria in low-and-middle-income countries (LMICs). LMICs, a term originally defined by the World Bank 1, are often the most impacted by such diseases.
The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities to address substantial global health concerns, for which investment incentives are limited.
References
- 1 World Bank. World Bank Country and Lending Groups Data Sheet. 2022 https://datahelpdesk.worldbank.org/knowledgebase/articles/906519
Pipeline Overview
We have a total of 9 assets across four business programs, which include three development programs in pre-clinical stage, four programs in clinical phase 1, one in clinical phase 2, and one in clinical phase 3.
Expanded Access Policy
To support our mission, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our interventions broadly available as quickly as possible, and we are privileged to collaborate with our development partners, clinical trial investigators, community advisory boards, and with participants in our clinical trials supporting our development programs. The Gates MRI is focused on evaluating investigational products in clinical trials and does not have an expanded access program for investigational products. Information about Gates MRI-sponsored clinical trials can be found on our website and on clinical trial registries, e.g., https://clinicaltrials.gov/ under trials listed for Gates Medical Research Institute.
Research Priorities
Learn more about our research programs at the Gates MRI by clicking on the icons.
Tuberculosis
An infectious disease caused by Mycobacterium tuberculosis (Mtb) bacteria, spread by bacteria expelled into the air